GET DAILY SIGNALSTwist Bioscience (TWST): Assessing the Synthetic Biology Platform in a Changing Rate Environment
Key Takeaways
- Macro driver: A firming biotechnology funding environment and structurally rising demand for synthetic DNA and sequencing tools underpin the growth narrative, while higher-for-longer interest rates remain a key sensitivity for high-growth, pre-profit life-science names.
- Sector outlook: The synthetic biology (SynBio) and genomics markets are expanding as pharmaceutical, agricultural, and industrial customers adopt scalable DNA synthesis to accelerate research and development.
- Portfolio exposure: Revenue is concentrated across SynBio products, next-generation sequencing (NGS) tools, and biopharma-focused antibody discovery, giving exposure to multiple long-duration secular themes from one platform.
- Structural risk and opportunity: Negative net margins and elevated valuation multiples create volatility, while improving gross margins and a scalable silicon-based manufacturing model support the path toward profitability.
- Upcoming catalysts: Quarterly earnings and guidance, new biopharma partnership activity, and commercialization progress in emerging areas such as DNA data storage and AI-assisted drug discovery are the key near-term swing factors.
Business Model and Revenue Streams
Twist Bioscience has developed a proprietary silicon-chip platform that enables large-scale writing of DNA. This industrializes production of synthetic genes, oligonucleotide pools, and associated reagents. The business breaks down into three main areas: SynBio products serving therapeutics, diagnostics, chemicals, food, agriculture, and academic research; NGS tools such as library prep, exome, and custom panels; and biopharma offerings including precision DNA libraries for antibody engineering and affinity maturation.
The company’s long-term potential rests on the scalability of this platform and the continued decline in per-unit synthesis costs. Strategic work with Eli Lilly and other partners extends its reach into drug discovery. While single-stock exposure carries concentration risk, the multi-segment revenue base spreads demand across research, clinical, and industrial markets, which can help moderate swings tied to any single customer group. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Key Catalysts on the Horizon
Several developments could influence the company’s path forward:
- Earnings and guidance: Management’s revenue outlook and commentary on gross-margin progress remain closely followed. Sustained revenue growth above roughly 20 percent together with margin expansion would reinforce the path to profitability.
- Biopharma partnership momentum: Expanded collaborations in antibody discovery and AI-assisted drug development could increase recurring revenue and validate the platform’s role in modern therapeutic pipelines.
- AI and DNA data storage: Interest in DNA as a high-density storage medium and in AI-driven drug design represents a longer-term but potentially significant demand driver.
- Interest-rate backdrop: As a high-growth, pre-profit life-science firm, valuation multiples stay sensitive to changes in rate expectations and risk appetite among growth investors.
- Capital-market conditions: Biotechnology funding flows, including venture capital and IPO activity, affect the spending capacity of many customers.
Sector Dynamics and Macro Environment
The broader outlook for life-science and genomics companies depends on interest rates, healthcare research budgets, and innovation cycles. Lower or stabilizing rates have historically supported higher valuations for pre-profit growth companies by increasing the present value of future cash flows, whereas prolonged high rates can compress multiples and reduce speculative inflows.
Demand fundamentals continue to look constructive. Pharmaceutical and biotechnology firms keep investing in discovery, and synthetic DNA has become a core input for antibody engineering, gene editing, and diagnostics. Government and private genomics funding adds a relatively stable layer of demand. Advances in AI-driven drug discovery and falling sequencing costs further widen the addressable market, linking the platform to multi-year industry trends that extend beyond any single funding cycle. From what I see, these secular forces remain the primary support for the investment thesis.
Longer-Term Structural Trends
Over time, declining costs and rising precision of DNA synthesis continue to lower barriers to experimentation, expanding use in drug discovery, agriculture, and industrial biotech. Demographic shifts and the move toward personalized medicine sustain demand for genetic tools and antibody therapies. The intersection of biology with artificial intelligence—covering AI-guided drug design and experimental DNA data storage—could meaningfully enlarge the total addressable market over the next decade.
Offsetting these opportunities are structural risks: the company has not yet achieved sustained profitability, operates in a competitive and fast-evolving field, and exhibits high equity beta. The durability of gross-margin gains, the conversion of revenue growth into positive cash flow, and ongoing customer adoption will determine the multi-year trajectory more than short-term price moves.
AI Tools for Near-Term Trend Insights
In my research process, I often turn to Tickeron’s Trend Prediction Engine to obtain AI-driven forecasts on whether a stock may move bullish, bearish, or sideways over the coming weeks or month. The tool helps identify developing trends, possible breakouts or reversals, and provides historical context across tradable instruments. It serves as a useful quantitative complement to fundamental and macro analysis when assessing near-term momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TWST sees MACD Histogram just turned negative
TWST saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 07, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 40 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for TWST moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 37 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 66 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
TWST moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 190 of 228 cases where TWST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.182) is normal, around the industry mean (2.988). TWST has a moderately low P/E Ratio (-66.874) as compared to the industry average of (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology
Advertisement